on July 22, 2004
Published online before print July 22, 2004, doi: 10.1161/01.ATV.0000140059.04717.f3
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on April 6, 2004
Accepted on July 12, 2004
Angiotensin II-Induced Insulin Resistance and Protein Tyrosine Phosphatases
Mario B. Marrero *;
From the Medical College of Georgia, Augusta, Ga.
* To whom correspondence should be addressed. E-mail: mmarrero{at}mail.mcg.edu.
Abstract--Although the importance of protein tyrosine phosphorylation by tyrosine kinases in mitogenic signaling is well-accepted, recent studies also suggest that tyrosine dephosphorylation by protein tyrosine phosphatases (PTPases) play an equally important role. For example, both angiotensin II (Ang II) and insulin are known to mediate protein tyrosine phosphorylation and dephosphorylation events. These apparently paradoxical effects of Ang II and insulin suggest that both convergent and divergent intracellular signaling cascades are stimulated downstream of their respective receptors, producing diverse cellular responses. In this review, we discuss the hypothesis that the protein tyrosine phosphatase (PTPase), PTP-1B, plays a central role in Ang II-induced insulin resistance by inhibiting activation of the insulin receptor. We hypothesize that Ang II-induced PTP-1B activation leads to dephosphorylation of the insulin receptor and that this signaling pathway underlies the maladaptive responses observed in diabetic vascular and renal tissue during type II diabetes.
This article has been cited by other articles:
 |
|
 |
|
  I. Tabbi-Anneni, J. Buchanan, R. C. Cooksey, and E. D. Abel Captopril Normalizes Insulin Signaling and Insulin-Regulated Substrate Metabolism in Obese (ob/ob) Mouse Hearts Endocrinology, August 1, 2008; 149(8): 4043 - 4050. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ruiz, P. Singh, S. C. Thomson, K. Munger, R. C. Blantz, and F. B. Gabbai L-arginine-induced glomerular hyperfiltration response: the roles of insulin and ANG II Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2008; 294(5): R1744 - R1751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Henriksen Improvement of insulin sensitivity by antagonism of the renin-angiotensin system Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2007; 293(3): R974 - R980. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Aronson, H. Hammerman, M. R. Kapeliovich, A. Suleiman, Y. Agmon, R. Beyar, W. Markiewicz, and M. Suleiman Fasting Glucose in Acute Myocardial Infarction: Incremental value for long-term mortality and relationship with left ventricular systolic function Diabetes Care, April 1, 2007; 30(4): 960 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Mehta and K. K. Griendling Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system Am J Physiol Cell Physiol, January 1, 2007; 292(1): C82 - C97. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Molavi, J. Chen, and J. L. Mehta Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H687 - H693. [Abstract] [Full Text] [PDF]
|
|